ATE484294T1 - Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen - Google Patents

Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen

Info

Publication number
ATE484294T1
ATE484294T1 AT05009688T AT05009688T ATE484294T1 AT E484294 T1 ATE484294 T1 AT E484294T1 AT 05009688 T AT05009688 T AT 05009688T AT 05009688 T AT05009688 T AT 05009688T AT E484294 T1 ATE484294 T1 AT E484294T1
Authority
AT
Austria
Prior art keywords
interleukin
antibodies
treatment
receptor
bronchial hyperresponsiveness
Prior art date
Application number
AT05009688T
Other languages
German (de)
English (en)
Inventor
W Lee Maloy
Prasad U Kari
Nicholas Nicolaides
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of ATE484294T1 publication Critical patent/ATE484294T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5425—IL-9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT05009688T 1995-08-24 1996-08-23 Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen ATE484294T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US276595P 1995-08-24 1995-08-24
US2380096P 1996-08-06 1996-08-06

Publications (1)

Publication Number Publication Date
ATE484294T1 true ATE484294T1 (de) 2010-10-15

Family

ID=26670837

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05009688T ATE484294T1 (de) 1995-08-24 1996-08-23 Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
AT96929657T ATE307203T1 (de) 1995-08-24 1996-08-23 Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96929657T ATE307203T1 (de) 1995-08-24 1996-08-23 Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma

Country Status (10)

Country Link
EP (3) EP1632248B8 (enExample)
JP (3) JP3948495B2 (enExample)
AT (2) ATE484294T1 (enExample)
AU (1) AU6895696A (enExample)
CA (2) CA2666298A1 (enExample)
DE (2) DE69635305T2 (enExample)
DK (2) DK1632248T3 (enExample)
ES (2) ES2249786T3 (enExample)
PT (1) PT1632248E (enExample)
WO (1) WO1997008321A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
CA2689842A1 (en) * 1996-12-02 1998-06-11 Genaera Corporation Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
AU746595B2 (en) * 1996-12-02 2002-05-02 Genaera Corporation IL-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
WO1998027997A1 (en) * 1996-12-20 1998-07-02 Magainin Pharmaceuticals Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
CA2302782A1 (en) * 1997-09-19 1999-03-25 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
JP2001517682A (ja) * 1997-09-19 2001-10-09 マガイニン ファーマシューティカルズ インク． 喘息および関連疾患を含むアトピー性アレルギーを治療するための標的としての喘息関連因子
EP1181037A4 (en) * 1999-05-01 2006-01-18 Genaera Corp FACTORS ASSOCIATED WITH ASTHMA AS TARGETS FOR TREATING ATOPIC ALLERGIES, ESPECIALLY ASTHMA AND RELATED DISORDERS
AU2001238079A1 (en) * 2000-02-09 2001-08-20 Med Immune, Inc. Antibody gene therapy with adeno-associated viral vectors
WO2002068594A2 (en) * 2001-02-22 2002-09-06 The Research Foundation Of State University Of New York Opiate receptors
EP1401497B1 (en) 2001-06-08 2012-01-11 Genaera Corporation Methods for the modulation of il-13
AU2004229527B2 (en) * 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
EP1771565B1 (en) 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
EP2364998A1 (en) 2005-06-16 2011-09-14 The Feinstein Institute for Medical Research Antibodies against HMGB1 and fragments thereof
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
JP5564167B2 (ja) * 2008-05-22 2014-07-30 日本たばこ産業株式会社 苦味マスキング剤及び苦味低減方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5414071A (en) 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
JPH09511400A (ja) 1994-03-30 1997-11-18 ユニバーシティ オブ メリーランド アット ボルティモア 交互スプライシングによって生成されるヒトインターロイキン変異体

Also Published As

Publication number Publication date
CA2230240C (en) 2009-08-18
JP4813380B2 (ja) 2011-11-09
EP1632248B8 (en) 2010-12-29
PT1632248E (pt) 2010-12-28
DE69635305D1 (de) 2006-03-02
DE69635305T2 (de) 2006-07-06
EP1632248B1 (en) 2010-10-13
EP2241329A3 (en) 2011-03-09
CA2666298A1 (en) 1997-03-06
EP0846173A1 (en) 1998-06-10
ATE307203T1 (de) 2005-11-15
JP2007169287A (ja) 2007-07-05
JP2011152135A (ja) 2011-08-11
JPH11514851A (ja) 1999-12-21
CA2230240A1 (en) 1997-03-06
DK1632248T3 (da) 2011-01-24
AU6895696A (en) 1997-03-19
EP1632248A1 (en) 2006-03-08
EP0846173B1 (en) 2005-10-19
ES2249786T3 (es) 2006-04-01
EP2241329A2 (en) 2010-10-20
DE69638281D1 (de) 2010-11-25
JP3948495B2 (ja) 2007-07-25
DK0846173T3 (da) 2006-01-16
ES2354360T3 (es) 2011-03-14
WO1997008321A1 (en) 1997-03-06

Similar Documents

Publication Publication Date Title
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
DE69609868D1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE3869490D1 (de) Verfahren zur elektrochemischen behandlung von stoffen.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69022249D1 (de) Knochenwachsapplikator zur Behandlung von Knochengewebe.
DE3687069D1 (de) Verwendung von 3&#39;-azido-3&#39;-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
DE69526437D1 (de) Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens
DE3882775D1 (de) Zusammensetzung zur behandlung von parodontaler krankheit.
ATA902789A (de) Verfahren zur katalytischen behandlung von abwasser
DE69004189D1 (de) Anordnungen zur behandlung menschlichen oder tierischen abfalls mittels mikrowellen.
DE69607559D1 (de) Verfahren zur Behandlung von Phenolteer
ATE213163T1 (de) Verfahren zur behandlung von motorischen defiziten
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE3856329D1 (de) Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
DE69111324D1 (de) Vorrichtung zur Behandlung oder Trennung von Gasen.
DE68903208D1 (de) Verfahren zur thermischen behandlung von laktoferrin.
DE69006509D1 (de) Verfahren zur behandlung von häuten.
DE3886755D1 (de) Verfahren zur behandlung von gefässkrankheiten.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE68903930D1 (de) Lipidemulsion zur behandlung von aids.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1632248

Country of ref document: EP